Press Releases May 1, 2026 12:20 PM

UPDATE – eXp World Holdings to Announce First Quarter 2026 Results on May 11, 2026

eXp World Holdings schedules first quarter 2026 earnings release and investor Q&A on May 11, 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
EXPI

eXp World Holdings, Inc., a Nasdaq-listed company and parent of eXp Realty, FrameVR.io, and SUCCESS Enterprises, announced it will report its Q1 2026 financial results on May 11, 2026. The company will also conduct a virtual fireside chat and investor Q&A session on the same day to discuss results and answer shareholder inquiries.

UPDATE – eXp World Holdings to Announce First Quarter 2026 Results on May 11, 2026
EXPI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • eXp World Holdings to report Q1 2026 earnings on May 11, 2026.
  • A virtual investor event including a fireside chat and Q&A will be held on earnings day.
  • The company operates a cloud-based real estate brokerage platform with global operations, highlighting its innovative and agent-centric business model.

BELLINGHAM, Wash., May 01, 2026 (GLOBE NEWSWIRE) -- eXp World Holdings, Inc. (Nasdaq: EXPI), the holding company for eXp Realty®, FrameVR.io and SUCCESS® Enterprises, today announced it expects to report its first quarter 2026 financial results on Monday, May 11, 2026. 

The Company will hold a virtual fireside chat and investor Q&A on Monday, May 11, 2026 at 5:30 a.m. PT / 8:30 a.m. ET hosted by:

  • Glenn Sanford, Founder, Chairman and CEO, eXp World Holdings
  • Leo Pareja, CEO, eXp Realty
  • Jesse Hill, Chief Financial Officer, eXp World Holdings

The investor Q&A is open to investors, current stockholders and anyone interested in learning more about eXp World Holdings and its companies. Submit questions in advance to investors@eXpWorldHoldings.com.

First Quarter 2026 Investor Q&A
Date: Monday, May 11, 2026
Time: 5:30 a.m. PT / 8:30 a.m. ET
Location: exp.world. Join at https://exp.world/earnings
Livestream: expworldholdings.com/events

About eXp World Holdings, Inc.

eXp World Holdings, Inc. (Nasdaq: EXPI) is the parent company of eXp Realty®, “the most agent-centric™ real estate brokerage on the planet,” FrameVR.io and SUCCESS® Enterprises. Through a cloud-based platform and agent-centric model, eXp Realty empowers real estate professionals with industry-leading commission structures, revenue share, equity ownership, and access to a global community. With operations spanning the Americas, Europe, the Middle East, Asia Pacific, and South Africa, eXp continues to redefine how agents connect, grow, and succeed in real estate. As a publicly traded company, eXp World Holdings prioritizes transparency, innovation, and long-term value for agents, staff, and shareholders.

Media Relations Contact:

eXp World Holdings, Inc.

mediarelations@expworldholdings.com

Investor Relations Contact:

Denise Garcia

investors@expworldholdings.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/abdc5523-d985-4c87-934d-323cf10c3716


Risks

  • Financial results may not meet investor expectations, impacting share price.
  • Global operational challenges across multiple regions could affect business performance.
  • Market competition in the real estate and virtual platform sectors may pose ongoing risks.

More from Press Releases

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026